The potential growth difference for the Krabbe disease treatment market between 2021 and 2026 is $438.03M. The market is driven by special drug designation. In addition, factors such as unmet clinical needs and the practice of consanguineous marriage will have an accelerating effect on the growth of the market. However, the limited patient pool for clinical trials will challenge market growth.
The anticonvulsants segment will have the largest share of the market. The segment is driven by the increased use of anticonvulsants in the treatment of convulsions or seizures, which is one of the main symptoms of Krabbe disease in infants. The market growth in the segment will be significant during the forecast period.
North America will be the leading region with 37% of the market's growth during the forecast period. The high incidence of Krabbe disease is driving the growth of the regional market.
For more highlights on the market size, CAGR, YOY growth rates, and other important statistics, according to a report by Technavio.
www.technavio.com/